Founded in 2018 by a team of accomplished scientists with a proven track record in drug discovery and executive leadership in top global biopharmaceutical companies, Regor is a pioneering international biotech company with headquarters in Shanghai, China and Boston, USA.

Our current therapeutic areas of interest include oncology, metabolic diseases and autoimmune diseases. By leveraging our industry-leading core strength in rCARD™ (Computer Accelerated Rational Discovery)...

+Read More+

News & Events


View All
  • 8 March, 2024

    Regor Initiates Phase 2 Study of Oral Once-daily GLP-1 Agonist RGT-075 for the Treatment of Obesity

    +Read More+

     

     

     

     

  • 7 December, 2023

    Regor Announces Promising Safety And Single Agent Efficacy Data Evaluating RGT-419B In HR+/HER2- Advanced Breast Cancer Patients Who Have Progressed On CDK4/6 Inhibitors And Endocrine Therapy

    +Read More+
  • 27 November, 2023

    Regor Announces Poster Presentations of RGT-419B, A Next Generation CDK4 Inhibitor at the San Antonio Breast Cancer Symposium (SABCS)

     

     

     

    +Read More+
  • 03 November, 2022

    Regor announces China NMPA approval of the IND for RGT-264 phosphate tablet, a potent and selective HPK1 inhibitor

     

    +Read More+
  • 20 April, 2022

    Regor announces China NMPA approval of the IND for RGT-419B capsule, a CDK2/4/6 inhibitor for advanced/metastatic breast cancer

    +Read More+
  • 12 April, 2022

    Regor announces the first patient dosed in the U.S. in the Phase II clinical trial for RGT-075, a novel small molecule GLP-1R agonist

     

    +Read More+
  • 8 April, 2022

    Regor announces the first patient dosed in the U.S. in the Phase I clinical trial for RGT-419B, a CDK2/4/6 inhibitor for advanced/metastatic breast cancer

    +Read More+
  • 10 Dec, 2021

    Regor and Lilly Enter into Strategic Collaboration to Discover and Develop Novel Therapies for Metabolic Disorders

    +Read More+
  • 18 Feb, 2021

    Regor Therapeutics Announces Completion of $90 Million Series B Financing

    +Read More+

Core Technologies

rCARD™, Computer Accelerated Rational Discovery, is a powerful and proprietary technology platform

+ Read more +

Pipeline

Initiated over 15 discovery projects since the inception of Regor

+ Read more +

Career Opportunities

View All

Accelerated Discovery. Breakthrough Medicines.

To serve patients around the world through innovative and clinically differentiated drugs

To accelerate portfolio delivery and value creation through enabling technology platforms

245 Main Street, Second Floor, Cambridge, MA 02142, USA
1206 Zhangjiang Rd, Building C, Pudong New District, Shanghai 201210, China